Cognitive-enhancing activity of thymol and carvacrol in two rat models of dementia

被引:81
作者
Azizi, Zahra [1 ]
Ebrahimi, Shima [1 ]
Saadatfar, Elshaan [1 ]
Kamalinejad, Mohammad [2 ]
Majlessi, Nahid [1 ]
机构
[1] Pasteur Inst Iran, Dept Physiol & Pharmacol, Tehran 1316943551, Iran
[2] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Pharmacognosy, Tehran, Iran
来源
BEHAVIOURAL PHARMACOLOGY | 2012年 / 23卷 / 03期
关键词
Alzheimer's disease; amyloid beta; carvacrol; Morris water maze; scopolamine; thymol; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; ANTIINFLAMMATORY ACTIVITY; MICE INVOLVEMENT; ESSENTIAL OILS; INFLAMMATION; STRATEGIES; COMPONENTS; TOXICITY; MEMORY;
D O I
10.1097/FBP.0b013e3283534301
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
This study evaluated the efficacy of thymol and carvacrol against cognitive deficits induced by amyloid beta (A beta) or scopolamine. Rats received bilateral intrahippocampal injections of A beta(25-35) or intraperitoneal injections of scopolamine, and the effect of different doses of thymol, or carvacrol (0.5, 1, or 2 mg/kg) on cognitive function was determined. Animals were subjected to 5 days of training in the Morris water maze: 4 days with an invisible platform to test spatial learning and the 5th day with a visible platform to test motivation and sensorimotor coordination. The acute toxicities of thymol and carvacrol were also studied. The results showed increases in escape latency and decreases in target quadrant entries in A beta or scopolamine-treated groups. These impairments were reversed by pretraining administration of either thymol or carvacrol. The calculated LD50's of thymol (565.7 mg/kg) and carvacrol (471.2 mg/kg) were found to be much higher than their therapeutic doses (thymol 0.5 mg/kg, carvacrol 1 mg/kg). These findings provide preliminary positive evidence for the effectiveness and safety of thymol and carvacrol in alleviating cognitive impairments caused by increased A beta levels or cholinergic hypofunction. Anticholinesterase, antioxidant, and anti-inflammatory activities may be the mechanisms contributing toward their beneficial effects in these models. Behavioural Pharmacology 23: 241-249 (C) 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:241 / 249
页数:9
相关论文
共 66 条
[1]   ANTIOXIDANT ACTIONS OF THYMOL, CARVACROL, 6-GINGEROL, ZINGERONE AND HYDROXYTYROSOL [J].
AESCHBACH, R ;
LOLIGER, J ;
SCOTT, BC ;
MURCIA, A ;
BUTLER, J ;
HALLIWELL, B ;
ARUOMA, OI .
FOOD AND CHEMICAL TOXICOLOGY, 1994, 32 (01) :31-36
[2]   Inflammation and Alzheimer's disease [J].
Akiyama, H ;
Barger, S ;
Barnum, S ;
Bradt, B ;
Bauer, J ;
Cole, GM ;
Cooper, NR ;
Eikelenboom, P ;
Emmerling, M ;
Fiebich, BL ;
Finch, CE ;
Frautschy, S ;
Griffin, WST ;
Hampel, H ;
Hull, M ;
Landreth, G ;
Lue, LF ;
Mrak, R ;
Mackenzie, IR ;
McGeer, PL ;
O'Banion, MK ;
Pachter, J ;
Pasinetti, G ;
Plata-Salaman, C ;
Rogers, J ;
Rydel, R ;
Shen, Y ;
Streit, W ;
Strohmeyer, R ;
Tooyoma, I ;
Van Muiswinkel, FL ;
Veerhuis, R ;
Walker, D ;
Webster, S ;
Wegrzyniak, B ;
Wenk, G ;
Wyss-Coray, T .
NEUROBIOLOGY OF AGING, 2000, 21 (03) :383-421
[3]   Can herbs provide a new generation of drugs for treating Alzheimer's disease? [J].
Anekonda, TS ;
Reddy, PH .
BRAIN RESEARCH REVIEWS, 2005, 50 (02) :361-376
[5]  
Aristatile Balakrishnan, 2009, Journal of Basic and Clinical Physiology and Pharmacology, V20, P15
[6]   Hypotensive effects of carvacrol on the blood pressure of normotensive rats [J].
Aydin, Yasemin ;
Kutlay, Oezden ;
Ari, Senem ;
Duman, Seval ;
Uzuner, Kubilay ;
Aydin, Sfileyman .
PLANTA MEDICA, 2007, 73 (13) :1365-1371
[7]   THE CHOLINERGIC HYPOTHESIS OF GERIATRIC MEMORY DYSFUNCTION [J].
BARTUS, RT ;
DEAN, RL ;
BEER, B ;
LIPPA, AS .
SCIENCE, 1982, 217 (4558) :408-417
[8]  
Basch Ethan, 2004, Journal of Herbal Pharmacotherapy, V4, P49, DOI 10.1080/J157v04n01_07
[9]  
Baser KHC, 2008, CURR PHARM DESIGN, V14, P3106, DOI 10.2174/138161208786404227
[10]   Novel Regimens and Delivery Systems in the Pharmacological Treatment of Alzheimer's Disease [J].
Bassil, Nazem ;
Grossberg, George T. .
CNS DRUGS, 2009, 23 (04) :293-307